Dengue Doctor’s Consultation Service and Vaccination for Ages 12-45 (3 doses)
Dengue is affecting 5x more Singaporeans in 2019, compared to previous years.
Just within Singapore, more than 11,000* people have caught dengue fever since January this year. This is already 5,000 more cases than the combined total of 2018 and 2017.
Why is dengue a major health concern?
If the spread of dengue is not controlled, having more infected people increases the chance of transmission to even more people -- a dangerous health hazard to the community.
On an individual level, dengue victims typically suffer from:
- persistent symptoms such as weakness and headache, for up to 6 months
- having to stay in bed for more than a week, feeling nauseous
- unable to go to work/school for up to 10 days
- in some cases, there is a more life-threatening form of dengue, called Severe/haemorrhagic dengue.
Prior dengue infection does not confer protection from future dengue infections. In fact, if you have a prior infection with the dengue virus, you have an increased risk of Severe/Haemorrhagic dengue and Dengue Shock Syndrome.
Severe Dengue symptoms include: severe abdominal pain, persistent vomiting, bleeding from your gums or nose, blood in your urine, stools or vomit, bleeding under the skin, which might look like bruising, difficult or rapid breathing, cold or clammy skin, fatigue, irritability or restlessness.
Who is eligible for the vaccination?
Only people from12-45 years of age, with evidence of previous dengue infection. (blood test or verifiable medical records showing positive results for dengue antibodies).
A Pre-vaccination dengue screening test can be taken assess if there has been previous infection if you are uncertain of your prior dengue infection status.
Available here : Dengue Pre-vaccination Blood Test.
How does Vaccination benefit people who are eligible?
The dengue vaccine(Dengvaxia) has been tested in large scale clinical safety and efficacy trials, involving 40000 people from 15 countries. (between ages 12-45). The results have shown a clear, durable benefit lasting 5 years:
The Health Sciences Authority approved the use of Dengvaxia in Singapore.
Price is applicable for three doses only and includes practice cost and doctor’s consultation charge at first visit.
Applicable at selected Raffles Medical (Singapore) clinics:
- Singapore Land Tower
- REMC (Raffles Hospital)
- Causeway Point
- Jurong East
- Tampines 1
- Compass One
- Ang Mo Kio
- Lot 1 Shoppers' Mall
- Changi Airport Terminal 3 B2
- Siglap Centre
Terms and conditions apply.
Upon purchase, we will send to your email a redemption letter that you can use to redeem your vaccination. Please refer to your redemption letter to select your preferred clinic prior to your visit and present the same letter, and your blood test results on the day of your vaccination. Price is in Singapore dollars and inclusive of GST.
*as of Aug numbers, data from National Environment Agency (NEA)
Precautions to note:
Terms and Conditions
What is dengue?
Dengue is a viral disease spread by Aedes mosquitoes, which can be painful and life-threatening. It is common in tropical regions, including Singapore.
Dengue is a national health concern, with a surge of cases in 2019
How does dengue affect humans ?
What are the symptoms of dengue fever?
Second-time infection has a higher chance to lead to severe/haemorrhagic dengue, which is life-threatening.
Fortunately, there is now a vaccine for dengue
Who is suitable for dengue vaccination?
Anyone between the ages of 12-45, who has a previous episode of dengue infection (including asymptomatic cases). Pre-vaccination - an antibodies test can be taken to assess if there has been previous infection.
How many doses are required?
The vaccination regime requires three doses to be given over a period of 12-months, at month 0, 6 and 12.
How has Dengvaxia proven to be effective?
Dengvaxia has been evaluated in studies involving > 40,000 people from 15 countries with up to six years of follow-up from large-scale clinical safety and efficacy investigations.1
The pivotal phase III large scale efficacy and safety trials were conducted in 10 endemic countries.
* Based on comparable immunogenicity profiles in adult populations and the phase III population, a similar level of protection by Dengvaxia® can be expected in individuals up to 45 years of age. Dengvaxia is approved in Singapore for 12 to 45 years old with past dengue infection. Please refer to the full Product Inform ati on before prescribing Dengvaxia ®
1. Sanofi Pasteur. Press Release . D engvaxia ® vaccine approved for prevention of dengue in Europe. 19 Dec 2018. Available at https://www.sanofipasteur.com/en/media room/press releases/dengvaxia vaccine approved for prevention of dengue in europe . Last accessed Aug 2019. 2. Villar L et al. N Engl J Med 2015;372(2):113 123. 3. Capeding MR, et al. Lancet 2014;384(9951):1358 1365 .
Dengvaxia efficacy in previously infected individuals1,2
Pooled efficacy analysis in 2,323 subjects 9-16 years of age who were seropositive at baseline during the 25 month active phase
1. H adinegoro SR et al. N Engl J Med 2015;373:1195 1206 2. Dengvaxia Prescribing Information for Singapore. 3. WHO. Revised SAGE recommendation on use of dengue vaccine. 19 April 2018. Available at here Last accessed Aug 2019. 4. Dear Doctor Letter “Important Findings From A Supplementary Exploratory Study On Dengvaxia® To Assess Long Term Safety And Efficacy Of Dengvaxia® From Phase IIb/III Studies” 30 Nov 2018 . S anofi Pasteur.
Dengvaxia: The vaccine against severe dengue
Pooled results during the 25 month active phase of the phase III clinical trials (VE % [95% CI])†‡1 4
|Benefits||General Well Being|